# INTERCEPTA Workstream B Phase 1 — Closure Document (TEMPLATE)

**Status:** TEMPLATE — to be filled when Phase 1 implementation completes.
**Spec:** `INTERCEPTA_Workstream_B_Phase1_Specification.md` (tag `workstream-b-phase1-spec-locked`)
**Discipline:** Charter §9 (Scientific Honesty), Round 2.2c FAIL-honestly precedent, P15
**Authors:** Prasad Akula (CEO) & Claude (CSO/AI co-founder)

> **Filling guidance:** This template is structured so that when Phase 1 results emerge, the CSO fills sections in order. Each section has fixed prompts. Honest reporting overrides cosmetic completeness. If a gate FAILS, document the FAIL — do not retroactively adjust criteria.

---

## 0. Verdict header

**Phase 1 overall verdict:** [ PASS | PASS_WITH_CAVEATS | FAIL_HONESTLY ]

**Closure date:** [YYYY-MM-DD]
**Repository tag:** `workstream-b-phase1-shipped` (to be applied at closure)
**Artifacts produced:**
- [list of parquet files, JSON reports, log files, with sizes and HPC paths]

**One-paragraph summary:** [2-3 sentences. What was done. What gates PASSED/FAILED. What the next phase needs.]

---

## 1. Pre-flight discipline check

**Spec compliance:**
- [ ] Pre-registered configuration unchanged from `INTERCEPTA_Workstream_B_Phase1_Specification.md` §3
- [ ] All gate criteria from spec §2 applied as-locked
- [ ] Random state = 42 throughout (no per-run variation)
- [ ] Canonical KAALCURA module used (no re-implementation per spec §3.1)

**Anti-scope-creep check (per spec §9):**
- [ ] No additions beyond the 4 deliverables (per-cohort parquet + JSON × 4)
- [ ] No analyses beyond G1.1-G1.4 gates
- [ ] Drug response prediction NOT attempted (Phase 2 work)
- [ ] Cross-cohort H2 testing NOT attempted (Phase 2 work)

**P16 preservation check:**
- [ ] Prior session work intact (29 files preserved at tag `workstream-b-phase0-prior-work-preserved-2026-05-10`)
- [ ] Phase 0 data not modified
- [ ] Skeleton scripts preserved alongside filled implementations

---

## 2. Per-cohort gate results

### 2.1 LuCA Salcher 2022 atlas

**Cells in atlas:** [N_input]
**Cells scored:** [N_scored]
**Studies represented:** [N_studies]
**Overall cohort verdict:** [PASS | PASS_WITH_CAVEATS | FAIL]

| Gate | Threshold | Observed | Verdict |
|---|---|---|---|
| G1.1 Gene coverage R_prolif | ≥60% | [%] | [PASS|FAIL] |
| G1.1 Gene coverage R_emt | ≥60% | [%] | [PASS|FAIL] |
| G1.1 Gene coverage R_ddr | ≥60% | [%] | [PASS|FAIL] |
| G1.2 NaN < 1% | <1% | [%] | [PASS|FAIL] |
| G1.2 Zeros < 5% | <5% | [%] | [PASS|FAIL] |
| G1.2 SD ≥ 0.1 | ≥0.1 | [σ] | [PASS|FAIL] |
| G1.3 Malignant > stromal R_prolif | direction match | [observed] | [PASS|FAIL] |
| G1.4 Sample size | ≥1M cells | [N] | [PASS|FAIL] |

**Notes / caveats specific to LuCA:**
- [Gene coverage notes — was the 60% LuCA threshold appropriate for this HVG-integrated atlas?]
- [scVI-integrated reduced dimensions vs raw expression — which was scored?]
- [Cell-type face validity: list median R_prolif by cell type]

---

### 2.2 Wu 2021

**Cells loaded:** [N_input]
**Cells scored:** [N_scored]
**Patients represented:** [N_patients] (expected 42)
**Overall cohort verdict:** [PASS | PASS_WITH_CAVEATS | FAIL]

| Gate | Threshold | Observed | Verdict |
|---|---|---|---|
| G1.1 Gene coverage R_prolif | ≥70% | [%] | [PASS|FAIL] |
| G1.1 Gene coverage R_emt | ≥70% | [%] | [PASS|FAIL] |
| G1.1 Gene coverage R_ddr | ≥70% | [%] | [PASS|FAIL] |
| G1.2 distribution sanity | per spec | [details] | [PASS|FAIL] |
| G1.3 marker-based cell-type validity | epithelial > stromal | [direction] | [PASS|FAIL] |
| G1.4 Sample size | ≥80K cells | [N] | [PASS|FAIL] |

**Notes / caveats specific to Wu:**
- [Cell typing was marker-based, not author-labeled — which markers gave clean labels?]
- [Per-sample CSV concatenation: any sample failures?]
- [LUAD/LUSC subtype mapping completeness]

---

### 2.3 TCGA-LUAD

**Samples loaded:** [N_input] (expected ~601)
**Samples scored:** [N_scored]
**Mutation annotations attached:** [N with MAF coverage]
**Overall cohort verdict:** [PASS | PASS_WITH_CAVEATS | FAIL]

| Gate | Threshold | Observed | Verdict |
|---|---|---|---|
| G1.1 Gene coverage R_prolif | ≥85% | [%] | [PASS|FAIL] |
| G1.1 Gene coverage R_emt | ≥85% | [%] | [PASS|FAIL] |
| G1.1 Gene coverage R_ddr | ≥85% | [%] | [PASS|FAIL] |
| G1.2 distribution sanity | per spec | [details] | [PASS|FAIL] |
| G1.4 Sample size | ≥550 samples | [N] | [PASS|FAIL] |

**Notes:**
- Ensembl→HGNC mapping coverage: [%]
- Mutation prevalence per gene: EGFR [%], KRAS [%], TP53 [%], STK11 [%], KEAP1 [%]
- Tissue PCA decomposition: [tumor purity range observed]

---

### 2.4 TCGA-LUSC

**Samples loaded:** [N_input] (expected ~562)
**Samples scored:** [N_scored]
**Mutation annotations attached:** [N with MAF coverage]
**Overall cohort verdict:** [PASS | PASS_WITH_CAVEATS | FAIL]

| Gate | Threshold | Observed | Verdict |
|---|---|---|---|
| G1.1 Gene coverage R_prolif | ≥85% | [%] | [PASS|FAIL] |
| G1.1 Gene coverage R_emt | ≥85% | [%] | [PASS|FAIL] |
| G1.1 Gene coverage R_ddr | ≥85% | [%] | [PASS|FAIL] |
| G1.2 distribution sanity | per spec | [details] | [PASS|FAIL] |
| G1.4 Sample size | ≥510 samples | [N] | [PASS|FAIL] |

**Notes:**
- LUSC-specific mutation prevalence: TP53 [%], CDKN2A [%], NOTCH1 [%], PIK3CA [%]
- Squamous vs adenocarcinoma EMT distribution differences observed?

---

## 3. Cross-cohort summary

**Coverage matrix:**

| Cohort | Cells/Samples | R_prolif coverage | R_emt coverage | R_ddr coverage |
|---|---|---|---|---|
| LuCA | [N] | [%] | [%] | [%] |
| Wu | [N] | [%] | [%] | [%] |
| TCGA-LUAD | [N] | [%] | [%] | [%] |
| TCGA-LUSC | [N] | [%] | [%] | [%] |

**Gate verdict matrix:**

| Cohort | G1.1 | G1.2 | G1.3 | G1.4 | Overall |
|---|---|---|---|---|---|
| LuCA | [PASS/FAIL] | [PASS/FAIL] | [PASS/FAIL] | [PASS/FAIL] | [verdict] |
| Wu | [PASS/FAIL] | [PASS/FAIL] | [PASS/FAIL] | [PASS/FAIL] | [verdict] |
| TCGA-LUAD | [PASS/FAIL] | [PASS/FAIL] | N/A (bulk) | [PASS/FAIL] | [verdict] |
| TCGA-LUSC | [PASS/FAIL] | [PASS/FAIL] | N/A (bulk) | [PASS/FAIL] | [verdict] |

**Cross-cohort coherence checks (per spec §6):**
- [ ] R_prolif distributions overlap across cohorts (sanity check; no formal threshold)
- [ ] Cell-type ranking (single-cell only) consistent between LuCA and Wu
- [ ] Tumor vs normal R_prolif difference (where applicable) in expected direction

---

## 4. CSO drift catalog (Phase 1)

Per Round 2.2c discipline, document any drift instances encountered during Phase 1 execution and how they were resolved.

| # | Drift instance | When caught | Resolution |
|---|---|---|---|
| P1.1 | [example: assumed Wu had author labels — caught by spec §3.4 reminder] | [stage] | [fix] |
| ... | | | |

**Total Phase 1 drift instances:** [N]
**All caught at runtime:** [Y/N]
**Reached final artifacts:** [N]

---

## 5. What Phase 1 produces for Phase 2

**Per-cohort scored data (Parquet, with mutation annotations where available):**
- LuCA: [path], [size], [N cells]
- Wu: [path], [size], [N cells]
- TCGA-LUAD: [path], [size], [N samples + mutations]
- TCGA-LUSC: [path], [size], [N samples + mutations]

**Cross-cohort summary:** [path to phase1_summary.json]

**Phase 2 readiness assessment:**
- H1 (cell-type ranking) requires LuCA + Wu PASS at G1.3 — [READY | BLOCKED]
- H2 (cross-cohort transfer Spearman correlation) requires all 4 cohorts at G1.4 PASS — [READY | BLOCKED]
- Mutation × axis association testing requires TCGA cohorts at G1.2 PASS — [READY | BLOCKED]

---

## 6. Failure handling (if any gate FAILED)

**If overall verdict is FAIL_HONESTLY:**

Per Charter §9 (Scientific Honesty) and Round 2.2c precedent:
- [ ] FAIL is documented HERE, not retroactively adjusted
- [ ] Diagnostic explanation provided (which gate, by how much, suspected cause)
- [ ] Phase 2 dependencies updated (what Phase 2 work is now blocked vs unblocked)
- [ ] Mitigation path identified (e.g., proxy genes for low coverage; spec amendment if criteria were unrealistic)
- [ ] FAIL declared without inflation; future-work status set to "deferred pending mitigation"

**If overall verdict is PASS_WITH_CAVEATS:**

- [ ] Caveats listed explicitly here with severity (low / medium / high)
- [ ] Caveats forwarded to Phase 2 spec to be incorporated
- [ ] No silent suppression of partial failures

---

## 7. Next-phase recommendations

**For Phase 2 spec authoring:**
- [Specific recommendations based on Phase 1 observations]
- [Cohort-specific design choices revealed by gate results]
- [Statistical power estimates from Phase 1 sample-size accounting]

**For repository hygiene:**
- [ ] Tag commit `workstream-b-phase1-shipped`
- [ ] Update `journal.txt` with Phase 1 closure entry
- [ ] Archive Phase 1 logs to `archive/phase1/` if needed
- [ ] Charter §6 Workstream B status: update to "Phase 1 shipped"

**For paper trajectory:**
- Phase 1 results enable [LuCA-only paper / cross-cohort transfer paper / wait for Phase 2]
- AML paper not affected (different workstream)

---

## 8. Closure declaration

**Phase 1 closes at:** [date]

**This closure document represents:**
- An honest record of what was tested
- An honest record of what passed and what failed
- A handoff to Phase 2 with explicit dependencies named
- A discipline checkpoint per Charter §9

**No spin. No goalpost-moving. No rationalization of FAIL as PASS.**

— Prasad Akula (CEO) & Claude (CSO)
[Closure date]

---

*Template version 1.0. Created 2026-05-10 alongside Phase 1 spec lock and skeleton scripts. Fill on Phase 1 implementation completion.*
